Highest-materiality recent filing
Vyome Holdings names Jerry Leonard CFO; interim CFO Dickey resigns
Jerry Leonard appointed Chief Financial Officer effective Sept 1, 2026, via ClearbridgeCFO consulting agreement.
Vyome Q2 2026 net loss $0.7M; advances VT-1953 FDA plan, in-licenses JAK inhibitors
Net loss of $720K ($0.10/share) for Q2 2026; cash $7.9M vs $5.0M at Dec 31, 2025.
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.
Vyome stockholders approve reducing authorized common shares from 300M to 50M
Stockholders voted to decrease authorized common stock from 300M to 50M shares; Certificate of Tenth Amendment filed.
Livechain acquires Humanyze debt for stock; seeks exchange uplisting
LICH acquired $5.765M senior secured convertible note of Humanyze from Remus Capital in exchange for 211.2M shares of LICH common stock (25% diluted stake).
Vyome reports positive Phase 2 data for VT-1953 in malignant fungating wounds; primary endpoint met
VT-1953 achieved significant reduction in malodor at Day 14 (p=0.002 vs baseline; p=0.0015 vs vehicle).
Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3
Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.
Vyome subsidiary LiveChain to acquire Remus Note for 25% of LICH stock; related-party deal
LICH will issue 25% of its fully diluted common stock to Remus for a Humanyze senior secured convertible note.
Vyome reports Q3 cash $5.7M; VT-1953 Phase 2 interim hits primary endpoint
VT-1953 Phase 2 interim data: statistically significant malodor reduction (p<0.001); pain and QoL improved; safety profile excellent.
Vyome Holdings shareholders elect three Class I directors, approve 2025 equity plan, ratify auditor
4,258,856 shares (77.52% of eligible) represented; all three Class I directors elected with ~3,955,642 votes for each.
Vyome acquires MIT AI startup Oculo Health to launch AI psychiatrist targeting inflammation
Acquired substantially all assets of Oculo, Inc., an MIT-launched AI startup.
Vyome corrected pro forma statements show combined net loss $522k, revenue $249k for H1 2025
Corrected pro forma for H1 2025: combined net loss $522k, revenue $249k, EPS $(0.07).
Vyome Holdings files pre-merger financials: H1 2025 net loss $603K, revenue $249K
Net loss of $602,732 for six months ended June 30, 2025, vs $593,132 in prior year.
Vyome Holdings increases ATM offering from $3.42M to $12M; appoints new auditor
Increased at-the-market offering capacity from $3.42M to $12M via Amendment to Equity Distribution Agreement with Maxim Group.
Vyome Holdings (HIND) completes merger and asset sale, appoints new CEO and board
Merger closed: Vyome Therapeutics becomes subsidiary; company renamed Vyome Holdings, Inc.
Stockholders approve asset sale to Ninjour Health and merger-related charter amendments
Asset Sale to Ninjour Health International Ltd approved: 1,273,715 For, 26,206 Against, 2,305 Abstentions.
Proposals 1,4,5,6 approved; meetings on asset sale (Prop 2) and merger charter (Prop 3) adjourned to Aug 7.
ReShape furnishes investor presentation for pending Vyome merger, new ticker HIND
Filed investor presentation slides on July 15, 2025 in connection with proposed merger with Vyome Therapeutics.
ReShape loans $200K to Vyome at 8% to fund merger-related expenses
ReShape (RSLS) issued a $200,000 promissory note to Vyome Therapeutics, bearing 8.0% interest per annum.
ReShape Lifesciences raises ~$6.3M to boost equity above Nasdaq $2.5M minimum
Raised $3.64M (593K shares) via ATM June 3-6, and $2.64M (1.05M shares) in direct offering June 9.
ReShape Lifesciences prices $2.6M public offering of 1.05M shares at $2.50 each
Offering of 1,054,604 shares closed on June 9, 2025; gross proceeds ~$2.6M.
ReShape Lifesciences prices $2.6M public offering of 1.05M shares at $2.50/share
Public offering of 1,054,604 shares at $2.50 per share; gross proceeds $2,636,510.
ReShape Lifesciences receives Nasdaq delisting notice; intends to appeal
Nasdaq determined to delist RSLS for failing to meet $2.5M stockholders' equity requirement by May 27, 2025 extension deadline.
ReShape Lifesciences enters $9.7M at-the-market equity distribution agreement with Maxim Group
Agreement allows sale of up to $9.7M of common stock via ATM offering; effective May 30, 2025.
Vyome Q1 2025 net loss widens to $294K; going concern raises risk for ReShape merger
Vyome revenue rose to $198.6K (Q1 2025) from $77.0K YoY, but net loss widened from $127K to $294K.
ReShape Lifesciences implements 1-for-25 reverse stock split effective May 9, 2025
Reverse stock split at 1-for-25 ratio effective at trading open on May 9, 2025; each 25 shares become 1.
ReShape Lifesciences amends asset purchase deal; price cut to $2.25M, deadline to June 30
Exercise price under Asset Purchase Agreement reduced from $5.16M to $2.25M.
ReShape Lifesciences provides $400k loan to Vyome, extends merger deadline to June 30
ReShape loans Vyome up to $400k in three tranches at 8% interest, due Sept 30, 2025.
Stockholders approve reverse split authorization, warrant exercise, and ELOC issuance
Authorized reverse stock split at ratio 1:2 to 1:250, board discretion within one year; 2,267,177 for, 26,063 against.
Gary Blackford resigns from Board effective March 15; Audit Committee short one member
Gary Blackford resigned from the Board and all committees effective March 15, 2025; not due to any disagreement with the Company.
ReShape Lifesciences prices $6M public offering of 2.6M units at $2.33/unit
Gross proceeds ~$6M from offering of 2,575,107 units at $2.33/unit; closed Feb 18, 2025.
ReShape Lifesciences amends convertible note, extends maturity to April 2025
Maturity extended to earlier of Vyome Therapeutics merger close or 90 days after Jan 14, 2025 (April 16, 2025).
ReShape Lifesciences enters up to $5M equity purchase agreement with investor
Equity purchase agreement for up to $5M over 36 months; pricing at 93% of prior-day VWAP with a true-up mechanism.
ReShape Lifesciences announces pending merger with Vyome Therapeutics; ticker to change to $HIND
Merger with Vyome Therapeutics Inc. and asset sale to Biorad Medisys or affiliate.
ReShape Lifesciences receives Nasdaq delisting notice for stockholders' equity below $2.5M
As of Sept 30, 2024, stockholders' equity was $1,487,000, below Nasdaq's $2.5M minimum.
ReShape reports Q3 rev $2.3M (+6.4% YoY); merger with Vyome, asset sale to Biorad for $5.16M
Q3 revenue $2.3M, up 6.4% YoY and 16.6% sequentially; gross margin 62.8%.
ReShape Lifesciences issues $833,333 senior secured convertible note to institutional investor
Issued $833,333.34 convertible note with 10% annual interest, due Jan 16, 2025 or upon close of Vyome merger.
ReShape Lifesciences announces 1-for-58 reverse stock split effective Sept 23, 2024
Reverse split ratio 1:58, effective at trading open on September 23, 2024.
ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M
Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.
ReShape Lifesciences announces reverse merger with Vyome Therapeutics and asset sale for $5.16M
Vyome stockholders will own 88.9% of combined company; ReShape stockholders to own 11.1%.
ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%
Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.
Effective April 8, 2024, RSM US LLP dismissed as independent auditor; Haskell & White LLP engaged for FY2024 and interim periods.
ReShape Lifesciences gets Nasdaq bid-price extension until Oct 7, 2024; may reverse split
Received Nasdaq Staff notice on April 9, 2024, that minimum $1.00 bid price still not met.
FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.
ReShape Lifesciences shareholders authorize reverse stock split up to 1:60 and elect directors
Shareholders authorized board to effect reverse stock split of common stock at ratio up to 1:60, within one year.
ReShape Lifesciences receives Nasdaq notice for missing annual meeting; reduces quorum
Nasdaq notified Jan 11, 2024 that company failed to hold annual meeting within 12 months of FYE 2022, violating Listing Rule 5620(a).
ReShape Lifesciences raises $1.2M via warrant exercise with existing accredited investor
Gross proceeds ~$1.2M from exercise of 5,382,500 warrants at reduced price of $0.23/share.
ReShape Q3 revenue down 21% to $2.2M; announces $8M cost cuts for 2024
Revenue $2.2M in Q3 2023, down from $2.8M in Q3 2022; nine-month revenue $6.7M, down 17%.
ReShape Lifesciences receives Nasdaq non-compliance notice for bid price below $1.00
Received Bid Price Notice on October 10, 2023 for failing to meet minimum $1.00 bid price per share.
ReShape Lifesciences prices $3.0M public offering at $0.33/unit; warrants amended
Offering of 9.1M units at $0.33/unit; each unit: 1 share (or pre-funded warrant) + 1.5 warrants exercisable at $0.33.
Gary Blackford informed the Board of Directors (the “Board”) of ReShape Lifesciences Inc. (the “Company”) of his decision to resign from the Board and all related committees effective March 15, 2025.
Mr. Bandy also resigned from the Board of Directors.
On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.
Mr. Hickey succeeds Bart Bandy, who has separated from the Company to pursue other opportunities.
On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.
Thomas Stankovich, Chief Financial Officer of the Company, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the Company.
Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Executive Chair, supporting Mr. Hickey and the Company on strategic matters
Max materiality 0.95 · Median 0.65 · Most common event other_material